Acute Lung Injury clinical trials at UC Irvine
1 research study open to eligible people
open to eligible people ages 18 years and up
Study objectives 1. To characterize the efficacy of reparixin in ameliorating lung injury and systemic inflammation and expediting clinical recovery and liberation from mechanical ventilation in adult patients with moderate to severe ARDS (PaO2/FIO2 ratio ≤ 200). 2. To evaluate the safety of reparixin vs. placebo in patients enrolled in the study.
Orange, California and other locations